The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
Official Title: A Phase 1/2 Study of Combination Lorlatinib and Ramucirumab in Patients With Advanced ALK-rearranged Lung Cancers
Study ID: NCT06007937
Brief Summary: This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they can test it in future participants to see if it is effective in treating their metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or DNA sequences associated with a response to treatment with lorlatinib and ramucirumab.
Detailed Description:
Minimum Age: 19 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities), Commack, New York, United States
Memorial Sloan Kettering West Harrison (All Protocol Activities), Harrison, New York, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Memorial Sloan Kettering Nassau (All Protocol Activities), Rockville Centre, New York, United States
Name: Gregory Riely, MD, PhD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR